Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2137222 | Leukemia Research | 2013 | 4 Pages |
Abstract
Recommendations for classification in AML have been published by the European Leukemia Network (ELN). We evaluated these recommendations within an independent cohort of 954 adult de novo AML patients. No differences in outcome for subgroups intermediate I versus II were found. Therefore we renewed the reporting system and defined the subgroups as follows: favorable (CBF leukemias, or intermediate cytogenetics with NPM1mutation (mut) or biallelic CEBPAmut), intermediate I (intermediate cytogenetics), intermediate II (intermediate cytogenetics and at least one of the following: MLL-PTD, RUNX1mut, FLT3-ITD/wt ratio ≥ 0.5), and adverse (adverse cytogenetics). Significant differences in outcomes between all four subgroups were found.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Tamara Alpermann, Wolfgang Kern, Susanne Schnittger, Christoph Schmid, Karl-Anton Kreuzer, Hubert Serve, Hermann Josef Pielken, Norbert Schmitz, Clemens-Martin Wendtner, Claudia Haferlach, Torsten Haferlach,